Loss of heterozygosity and mRNA expression at deleted in colorectal cancer gene locus in gastric cancer

Table 1 Relationship of loss of heterozygosity (LOH) and mRNA expression (LOE) of deleted in colorectal cancer (DCC) with clinicopathological parameters

Clinicopathologic parameters	LOH/informative (%)	LOE/No. examined (%)
Differentiation
Well/moderate	4/12 (33.3)	1/6 (16.7)
Poor	12/28 (42.9)	5/14 (35.7)
Mucinous carcinoma	2/11 (18.2)	2/6 (33.3)
Tumor size
< 5 cm	4/20 (20.0)	4/12 (33.3)
> 5 cm	14/31 (45.2)	4/14 (28.6)
Serosal invasion
Absent	4/18 (22.2)	3/12 (25.0)
Present	12/33 (36.4)	5/14 (35.7)
Lymph node metastasis
Absent	5/24 (20.8)	2/13 (15.4)
Present	13/27 (48.1)	6/13 (46.2)
Clinical staging
Stages I-II	3/21 (14.3)	2/11 (18.2)
Stages III-IV	15/30 (50.0)a	6/15 (40.0)

^aP < 0.05 as compared with that of stage I and II.

Table 2 Relationship between loss of heterozygosity (LOH) and mRNA expression (LOE) of deleted in colorectal cancer (DCC) gene

Groups	LOH	LOE	No. of cases (%)
1	+	+	4 (15.4)
2	-	-	14 (53.8)
3	-	+	4 (15.4)
4	+	-	4 (15.4)

+: Positive; and -: Negative.